Hala Kaaki

Head of Orphan Diseases Division

Venn Therapeutics is a highly innovative drug discovery incubator and immuno-oncology company developing a pipeline of novel, first-in-class agents that precisely target key mechanisms of cancer, fibrosis, and NASH, focused on integrin-mediated activation of TGF-β.Venn’s broad portfolio includes a pipeline of first-in-class antibodies targeting integrins for the treatment of cancer and fibrotic disorders. Venn leverages pioneering translational research working with world class scientific researchers at the cutting edge of the emerging field of immuno-oncology.